Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Recursion Pharmaceuticals
Biotech
Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival's data
Ovid is pumping the brakes on a planned phase 2 trial in a type of brain lesion while it considers any lessons from Recursion’s rival candidate.
James Waldron
Nov 13, 2024 8:15am
Recursion's brain disease trial shows scant evidence of efficacy
Sep 3, 2024 10:30am
After a tough year, Exscientia folds into Recursion
Aug 8, 2024 8:54am
Recursion, Canaan, Metsera and more—Chutes & Ladders
Apr 19, 2024 8:30am
Nvidia grows drug research footprint with Amgen, Recursion pacts
Jan 8, 2024 1:00pm
Recursion lines up $50M Nvidia collab for AI drug discovery
Jul 12, 2023 12:32pm
